Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
Go back to Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager| Consolidated Gems, Inc. (NASDAQ: CGEM) | Delayed: 17.75 +0.45 (2.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.30 | 52 Week High | $0.19 | |||
| Open | $16.80 | 52 Week Low | $0.03 | |||
| Day High | $17.98 | P/E | N/A | |||
| Day Low | $16.56 | EPS | $0.00 | |||
| Volume | 1,960,283 | |||||
